VivoSeq
Oncology

Combined Hepatocellular and Cholangiocarcinoma

4

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Combined Hepatocellular and Cholangiocarcinoma is an early-stage landscape with 4 programs across 3 companies. The most active players are AstraZeneca, Johnson & Johnson, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

2 programs

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody250%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab (STRIDE) Plus Gemcitabine and Cisplatin (GEMCIS) in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma (cHCC-CCA)
Not yet recruiting·—·Phase 2·NCT06855225·29 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)